Last reviewed · How we verify
Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients (SartSep)
The investigators propose a clinical study of irbersartan for the early treatment of severe sepsis patients with elevated predicted risk of death between. This study will evaluate whether early administration of the the angiotensin receptor blocker irbersartan provides significant reduction of 28 days mortality and multi organ failure incidence to patients with severe sepsis.
Details
| Lead sponsor | University of Salerno |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 300 |
| Start date | 2014-01 |
| Completion | 2017-01 |
Conditions
- Severe Sepsis
Interventions
- Irbesartan
Primary outcomes
- mortality — 28 days
Countries
Italy